Novo Norisk (OMX: NOVO B, NYSE: NVO) manufactures and markets pharmaceutical products and services. Created in 1989 through a merger of two Danish companies dating back to the 1920s, it has become one of the world's leading companies in diabetes care, including the products within the area of insulin delivery systems. Novo Nordisk also has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy.